Celgene Corp. Announces Appointment of Jonathan Biller as Executive Vice President & General Counsel Following the Departure ...
June 19 2018 - 3:30PM
Business Wire
Celgene Corporation (NASDAQ:CELG) today announced the
appointment of Jonathan Biller as Executive Vice President and
General Counsel effective July 3, 2018. Mr. Biller will be
responsible for global legal strategy and will serve on the
company's Executive Committee.
Mr. Biller will succeed Gerald F. Masoudi, Celgene's Executive
Vice President and General Counsel since 2015. Mr. Masoudi is
leaving Celgene to return to Washington, D.C. with his family and
assume the role of Chief Legal Officer with a private company
outside of the biopharmaceutical industry.
“Jonathan has been an integral part of Celgene’s senior
management team for the last seven years. He has led our capital
allocation strategy and provided industry-wide leadership on U.S.
corporate tax reform. His extensive legal experience and deep
understanding of Celgene enable him to immediately strengthen our
leadership team as General Counsel,” said Mark J. Alles, Chairman
and Chief Executive Officer of Celgene Corporation. “Jerry has made
many important contributions to Celgene, and we wish him and his
family all the best.”
Mr. Biller joined Celgene in 2011 and was most recently Senior
Vice President, Tax and Treasury and served as Celgene’s Treasurer.
He joined Celgene from Bunge Limited, a publicly traded agriculture
and food company, where he was General Counsel, Chief Tax Officer
and Secretary from 2008 to 2011. In this role, he managed a global
legal team of more than 100 professionals. Prior to Bunge, Mr.
Biller held roles of increasing responsibility at Alcon, Inc. He
began his legal career at Hopkins & Sutter before rising to the
level of partner and served as a partner at Foley & Lardner
after the firms merged. Mr. Biller holds a J.D. from Yale Law
School and a B.A. from Brown University.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in
the discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through next-generation solutions in protein homeostasis,
immuno-oncology, epigenetics, immunology and neuro-inflammation.
For more information, please visit www.celgene.com. Follow Celgene
on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and
YouTube.
Hyperlinks are provided as a convenience and for informational
purposes only. Celgene bears no responsibility for the security or
content of external websites.
Forward-Looking Statement
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," "outlook" and similar expressions. Forward-looking
statements are based on management's current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. We undertake no obligation to update any forward-looking
statement in light of new information or future events, except as
otherwise required by law. Forward-looking statements involve
inherent risks and uncertainties, most of which are difficult to
predict and are generally beyond our control. Actual results or
outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual
Report on Form 10-K and our other reports filed with
the Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180619006361/en/
CelgeneInvestors:908-673-9628ir@celgene.comorMedia:908-673-2275media@celgene.com
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024